Literature DB >> 32553378

Cognitive impairment in individuals with bipolar disorder with and without comorbid alcohol and/or cocaine use disorders.

Chengxi Li1, Jayme M Palka1, E Sherwood Brown2.   

Abstract

BACKGROUND: Bipolar disorder (BD) frequently co-occurs with substance use disorders (SUDs), and both are associated with cognitive impairment. This study compares cognition between individuals with BD with and without current alcohol use disorder (AUD), cocaine use disorder (CUD), or both, as these disorders may be linked with additive cognitive impairment.
METHODS: Baseline data were analyzed from five clinical studies of individuals with the aforementioned disorders (N = 373). Participants were grouped as follows: BD-only, BD + AUD, BD + CUD, or BD + AUD + CUD. Cognition was assessed with the Rey Auditory Verbal Learning Test (RAVLT) (verbal learning and memory) and Stroop Color Word Test (executive function). Multiple linear regression models determined if SUD diagnosis, among other demographic and clinical variables, predicted each cognitive test's T-score. Regression equations were used to compute each group's mean T-scores.
RESULTS: All groups demonstrated below-average mean T-scores on all tests, with no significant between-group score differences. RAVLT total T-scores were lower than Stroop color-word T-scores within all groups (non-overlapping 95% confidence intervals). Higher daily cocaine use predicted higher Stroop T-scores (p < 0.01) and RAVLT delayed recall T-scores (p < 0.05). No other non-demographic variable, including AUD/CUD group status, predicted cognitive performance. LIMITATIONS: A full cognitive battery and some relevant variables (e.g. BD lifetime illness course) were not available. Many participants (42.1%) had additional SUDs.
CONCLUSIONS: BD with and without AUD/CUD was found to be associated with greater deficits in verbal learning and memory than in executive function. Addressing these impaired domains in dually-diagnosed patients may improve treatment and functional outcomes.
Copyright © 2020. Published by Elsevier B.V.

Entities:  

Keywords:  Alcohol use disorder; Bipolar disorder; Cocaine use disorder; Cognitive impairment; Dual diagnosis; Executive function

Mesh:

Substances:

Year:  2020        PMID: 32553378      PMCID: PMC7305419          DOI: 10.1016/j.jad.2020.03.179

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  44 in total

1.  The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.

Authors:  Marilyn S Albert; Steven T DeKosky; Dennis Dickson; Bruno Dubois; Howard H Feldman; Nick C Fox; Anthony Gamst; David M Holtzman; William J Jagust; Ronald C Petersen; Peter J Snyder; Maria C Carrillo; Bill Thies; Creighton H Phelps
Journal:  Alzheimers Dement       Date:  2011-04-21       Impact factor: 21.566

2.  A pilot study of brexpiprazole for bipolar depression.

Authors:  E Sherwood Brown; Neusha Khaleghi; Erin Van Enkevort; Elena Ivleva; Alyson Nakamura; Traci Holmes; Brittany L Mason; Chastity Escalante
Journal:  J Affect Disord       Date:  2019-02-19       Impact factor: 4.839

3.  A Randomized, Double-Blind, Placebo-Controlled Trial of Citicoline for Cocaine Dependence in Bipolar I Disorder.

Authors:  E Sherwood Brown; Jackie Peterson Todd; Lisa T Hu; Joy M Schmitz; Thomas J Carmody; Alyson Nakamura; Prabha Sunderajan; A John Rush; Bryon Adinoff; Mary Ellen Bret; Traci Holmes; Alexander Lo
Journal:  Am J Psychiatry       Date:  2015-05-22       Impact factor: 18.112

4.  The effect of cognitive functioning on treatment attendance and adherence in comorbid bipolar disorder and cocaine dependence.

Authors:  Colleen S Fagan; Thomas J Carmody; Shawn M McClintock; Alina Suris; Alyson Nakamura; Haekyung Jeon-Slaughter; Alexander Lo; E Sherwood Brown
Journal:  J Subst Abuse Treat       Date:  2014-07-12

5.  Hippocampal volume and verbal memory performance in late-stage bipolar disorder.

Authors:  Bo Cao; Ives Cavalcante Passos; Benson Mwangi; Isabelle E Bauer; Giovana B Zunta-Soares; Flávio Kapczinski; Jair C Soares
Journal:  J Psychiatr Res       Date:  2015-12-15       Impact factor: 4.791

6.  The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression.

Authors:  A John Rush; Madhukar H Trivedi; Hicham M Ibrahim; Thomas J Carmody; Bruce Arnow; Daniel N Klein; John C Markowitz; Philip T Ninan; Susan Kornstein; Rachel Manber; Michael E Thase; James H Kocsis; Martin B Keller
Journal:  Biol Psychiatry       Date:  2003-09-01       Impact factor: 13.382

7.  Effect of alcohol and illicit substance use on verbal memory among individuals with bipolar disorder.

Authors:  Taiane de A Cardoso; Isabelle E Bauer; Karen Jansen; Robert Suchting; Giovana Zunta-Soares; João Quevedo; David C Glahn; Jair C Soares
Journal:  Psychiatry Res       Date:  2016-06-29       Impact factor: 3.222

8.  A randomized, double-blind, placebo-controlled add-on trial of quetiapine in outpatients with bipolar disorder and alcohol use disorders.

Authors:  E Sherwood Brown; Monica Garza; Thomas J Carmody
Journal:  J Clin Psychiatry       Date:  2008-05       Impact factor: 4.384

9.  Joint Effects: A Pilot Investigation of the Impact of Bipolar Disorder and Marijuana Use on Cognitive Function and Mood.

Authors:  Kelly A Sagar; M Kathryn Dahlgren; Megan T Racine; Meredith W Dreman; David P Olson; Staci A Gruber
Journal:  PLoS One       Date:  2016-06-08       Impact factor: 3.240

Review 10.  Cognitive Impairment in Bipolar Disorder: Treatment and Prevention Strategies.

Authors:  Brisa Solé; Esther Jiménez; Carla Torrent; Maria Reinares; Caterina Del Mar Bonnin; Imma Torres; Cristina Varo; Iria Grande; Elia Valls; Estela Salagre; Jose Sanchez-Moreno; Anabel Martinez-Aran; André F Carvalho; Eduard Vieta
Journal:  Int J Neuropsychopharmacol       Date:  2017-08-01       Impact factor: 5.176

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.